New Targeted Therapies for HER2-Positive Metastatic Breast Cancer

Gain multidisciplinary perspectives on how to leverage novel and established HER2-targeted agents for optimal mangement of HER2-positive metastatic breast cancer with these downloadable slides from expert-led workshops and Webinars.

Share

Program Content

Activities

HER2 MBC Tx Slides
New Targeted Therapies for HER2-Positive Metastatic Breast Cancer: Downloadable Slides
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 23, 2020

Expires: September 22, 2021

Faculty

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen